References
- Wood DM, Dargan PI. Novel psychoactive substances: how to understand the acute toxicity associated with the use of these substances. Ther Drug Monitoring 2012;34:363–367.
- Wood DM, Dargan PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol 2012; In press [DOI: 10.1007/s13181-012-0241-3].
- Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012; 8:33–42.
- Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011; 49:705–719.
- European Monitoring Centre for Drugs and Drug Addiction. Annual Report 2011: The state of the drugs problem in Europe. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_143743_EN_EMCDDA_AR2011_EN.pdf [Last accessed 9th July 2012].
- Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P. The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila) 2011; 49: 131–141.
- Advisory Council on the Misuse of Drugs: Consideration of Desoxypipradrol (2-DPMP) and related pipdradrol compounds. Available from:http://www.homeoffice.gov.uk/publications/agencies-public-bodies/acmd1/desoxypipradrol-report?view= Binary [last accessed 9th July 2012].
- Bellucci G. (2-Diphenylmethyl-piperidine hydrochloride and the methyl ester of 2-chloro-2-phenyl-2-(2-piperidyl)-acetic acid), drugs with waking effect in anaesthesia. Minerva Anestesiologica 1955; 21:125–128.
- Davidson C, Ramsey J. Desoxypipradrol is more potent than cocaine on evoked dopamine efflux in the nucleus accumbens. J Psychopharm 2012; 26:1036–1041.
- Pyrrolidine derivatives US patent application. (Jackson PF and Guildford Pharmaceuticals; Patent number 5,650,521). Available from: http://v3.espacenet.com/origdoc?CY = gb&LG = en&DB = EPODOC&IDX = US5650521&DOC = dcb65d04ab6724e097530cc48c44ebbb62 [Last accessed 9th July 2012].
- Herbert JX, Daly F, Tracey JA. Whacked. BMJ rapid response 15 July 2010. Available from: http://www.bmj.com/rapid-response/2011/11/02/whacked [Last accessed 9th July 2012].
- James DA, Potts S, Thomas SHL, Chincholkr VM, Clarke S, Dear J, Ramsey J. Clinical Features associated with recreational use of ‘Ivory Wave’ preparations containing desoxypipradrol. Clin Tox (Philad) 2011; 49:201.
- Murray DB, Potts S, Haxton C, Jackson G, Sandilands EA, Ramsey J, ‘Ivory Wave’ toxicity in recreational drug users: integration of clinical and poisons information services to manage legal high poisoning. Clin Tox (Phila) 2012; 50:108–113.
- Lidder S, Dargan PI, Sexton S, Button J, Ramsey J, Holt DW, Wood DM. Cardiovascular toxicity associated with recreational use of diphenylprolinol (diphenyl-2-pyrrolidinemethanol) [D2PM]). J Med Toxicol 2008; 4:167–169.
- Wood DM, Puchnarewicz M, Johnston A, Dargan PI. A case series of individuals with analytically confirmed acute diphenyl-2-pyrrolidinemethanol (D2PM) toxicity. Eur J Clin Pharmacol 2012; 68:349–353.
- Drugs Forum. Experiences 2-DPMP / desoxypipradol trip reports. Available from: http://www.drugs-forum.com/forum/showthread.php?t= 125430 [Last accessed 9th July 2012].
- Drugs Forum. Experiences - Diphenyl-2-Pyrrolidinyl-Methanol (diphenylprolinol) trip reports. Available from: http://www.drugs-forum.com/forum/showthread.php?t= 41534 [Last accessed 9th July 2012].
- Erowid (2-DPMP) Desoxypipradrol Reports. Available from: https://www.erowid.org/experiences/subs/exp_Desoxypipradrol_.shtml [Last accessed 9th July 2012].
- Erowid (D2PM) Diphenyl-2-pyrrolidinemethanol Reports. Available from: http://www.erowid.org/experiences/subs/exp_Diphenyl2pyrrolidinemethanol.shtml [Last accessed 9th July 2012].
- Blue Ray. Desoxypipradrol - First Experience - 5mg. Available from:http://www.bluelight.ru/vb/threads/363832-Desoxypipradrol-First-Experience-5mg [Last accessed 9th July 2012].
- European Monitoring Centre for Drugs and Drug Addiction. Briefing paper: Online sales of new psychoactive substances /'legal highs’: Summary of results from the 2011 multilingual snapshots. Available from:http://www.emcdda.europa.eu/attachements.cfm/att_143801_EN_SnapshotSummary.pdf" [Last accessed 9th July 2012].
- Dick D, Torrance C. Drugs Survey. MixMag 2010; 225:44–53.
- Winstock A. Drug Survey. MixMag2011; 238:50–59.
- Winstock A. MixMag / Global Drugs Survey. MixMag 2012; 251:68–73.
- Measham F, Wood DM, Dargan PI, Moore K. The rise in legal highs: prevalence and patterns in the use of illegal drugs and first- and second-generation “legal highs” in South London gay dance clubsJ Subs Use 2011; 16:263–272.
- Wood DM, Hunter L, Measham F, Dargan PI. Limited use of novel psychoactive substances in South London nightclubs. QJM 2012 In Press.
- Dargan PI, Button J, Hawkins L, Archer JR, Ovaska H, Lidder S, . Detection of the pharmaceutical agent glaucine as a recreational drug. Eur J Clin Pharmacol 2008; 64:553–554.
- Rovinskia VI. A case of hallucinogen-like action of glaucine. Klin Med (Mosk) 1989; 67:107–108.
- Rovinskia VI. Acute glaucine syndrome in the physician's practice: the clinical picture and potential danger. Klin Med (Mosk) 2006; 84:68–70.